A preclinical-stage company founded by gene-therapy pioneers from leading academic institutions including Stanford University, Tel Aviv University, and Children’s Medical Research Institute in Sydney, LogicBio designed its approach to harness the natural power of homologous recombination − enabling precise, site-specific transfer of the genetic material without the use of promoters or nucleases, which could be associated with unwanted side effects. The goal: provide patients with a functional version of a faulty, disease-causing gene to deliver a cure. LogicBio is advancing programs for rare, life-threatening pediatric genetic diseases − focusing first on inborn errors of metabolism, where there are few, if any, treatment options. ©LogicBio 2017 Illustration by O’Reilly Science Art LLC
A preclinical-stage company founded by gene-therapy pioneers from leading academic institutions including Stanford University, Tel Aviv University, and Children’s Medical Research Institute in Sydney, LogicBio designed its approach to harness the natural power of homologous recombination − enabling precise, site-specific transfer of the genetic material without the use of promoters or nucleases, which could be associated with unwanted side effects. The goal: provide patients with a functional version of a faulty, disease-causing gene to deliver a cure. LogicBio is advancing programs for rare, life-threatening pediatric genetic diseases − focusing first on inborn errors of metabolism, where there are few, if any, treatment options. ©LogicBio 2017 Illustration by O’Reilly Science Art LLC